These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 22539249)
1. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy. Stacchini A; Demurtas A; Aliberti S Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249 [TBL] [Abstract][Full Text] [Related]
2. Accidental overdose of intrathecal cytarabine in children. Thienprayoon R; Heym KM; Pelfrey L; Bowers DC Ann Pharmacother; 2013 May; 47(5):e24. PubMed ID: 23606548 [TBL] [Abstract][Full Text] [Related]
3. Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy. Swords R; O'Rafferty C; Giles F; Browne P Leukemia; 2008 Dec; 22(12):2277-8. PubMed ID: 18528421 [No Abstract] [Full Text] [Related]
4. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study. Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262 [TBL] [Abstract][Full Text] [Related]
5. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. Sancho JM; Deben G; Parker A; Piñana JL; Bolam S; Sánchez-García E; Giménez E; Pascual T; Fernández-Abellán P; Palomera L; Ribera JM Int J Hematol; 2007 Jul; 86(1):33-6. PubMed ID: 17675264 [TBL] [Abstract][Full Text] [Related]
6. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860 [TBL] [Abstract][Full Text] [Related]
8. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563 [TBL] [Abstract][Full Text] [Related]
10. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine. Prescrire Int; 2006 Feb; 15(81):11-2. PubMed ID: 16548098 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia. Duarte RF; Arnan M; Sánchez-Ortega I; de Llano MP; Abellán PF Leuk Res; 2011 Jul; 35(7):e128-30. PubMed ID: 21501870 [No Abstract] [Full Text] [Related]
12. [Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection]. Guillaume C; Vegas H; Pastuszka A; Le Brun C; Lanotte P Ann Biol Clin (Paris); 2018 Oct; 76(5):568-570. PubMed ID: 30154068 [TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Spina M; Chimienti E; Martellotta F; Vaccher E; Berretta M; Zanet E; Lleshi A; Canzonieri V; Bulian P; Tirelli U Cancer; 2010 Mar; 116(6):1495-501. PubMed ID: 20108270 [TBL] [Abstract][Full Text] [Related]
14. Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Counsel P; Khangure M Clin Radiol; 2007 Feb; 62(2):172-6. PubMed ID: 17207701 [No Abstract] [Full Text] [Related]
15. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213 [TBL] [Abstract][Full Text] [Related]
17. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. McClune B; Buadi FK; Aslam N; Przepiorka D Leuk Lymphoma; 2007 Sep; 48(9):1849-51. PubMed ID: 17786723 [No Abstract] [Full Text] [Related]
18. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. Seif AE; Reilly AF; Rheingold SR J Pediatr Hematol Oncol; 2010 Nov; 32(8):e349-52. PubMed ID: 20962675 [TBL] [Abstract][Full Text] [Related]
19. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818 [TBL] [Abstract][Full Text] [Related]
20. Paraplegia following intrathecal cytosine arabinoside. Wolff L; Zighelboim J; Gale RP Cancer; 1979 Jan; 43(1):83-5. PubMed ID: 282937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]